4 Healthcare Stock Stories for Tuesday Investment Wellness

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Eli Lilly and Company (NYSE:LLY): Current price $56.50

The company reported that it is working closely with the city of Indianapolis on a proposal to invest an additional $180 million in its insulin manufacturing operations. The investment will be in addition to its November 2012 announcement of a $140 million expansion of the same. All told, the investments would permit Lilly to satisfy the growing insulin demand, given the increase in diabetes prevalence across the United States. Lilly also is proposing a number of other ancillary investment projects totaling approximately $80 million, including a $40 million product-inspection center.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

LLY

Ampio Pharmaceuticals (NASDAQ:AMPE): Current price $4.62

On Tuesday, Ampio reported FDA acceptance of its IND and the treatment of the first 15 patients in its clinical trial using Ampion to treat osteoarthritis of the knee. The med is a non-steroidal anti-inflammatory biologic with the potential to be used in a wide array of inflammatory conditions and autoimmune diseases.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AMPE

Cleveland BioLabs (NASDAQ:CBLI): Current price $1.98

Cleveland BioLabs and Incuron, a joint venture between the firmer and Bioprocess Capital Ventures, have announced the receipt of a Notice of Allowance from the FDA for an Investigational New Drug application for CBL0137. The agency is finalizing a multi-center, Phase 1, single agent, dose escalation trial studying intravenous administration of CBL0137 in patients suffering from metastatic or unresectable advanced solid cancers.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CBLI

Zalicus (NASDAQ: ZLCS): Current price $0.67

The firm has been granted a patent by the United States Patent and Trademark office covering novel formulations of its product candidate Z160. United States patent number 8,409,560, entitled Solid Dispersion Formulations and Methods of Use Thereof, allows broad coverage for a range of novel Z160 pharmaceutical compositions and methods of using these compositions in the treatment of pain. Zalicus is a biopharmaceutical firm that discovers and develops novel treatments for patients suffering from pain.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ZLCS

Investing Insights: Is the New Abbot a Winner?

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business